Wuhan Coronavirus Resource Thread

The Strategic Issues & International Relations Forum is a venue to discuss issues pertaining to India's security environment, her strategic outlook on global affairs and as well as the effect of international relations in the Indian Subcontinent. We request members to kindly stay within the mandate of this forum and keep their exchanges of views, on a civilised level, however vehemently any disagreement may be felt. All feedback regarding forum usage may be sent to the moderators using the Feedback Form or by clicking the Report Post Icon in any objectionable post for proper action. Please note that the views expressed by the Members and Moderators on these discussion boards are that of the individuals only and do not reflect the official policy or view of the Bharat-Rakshak.com Website. Copyright Violation is strictly prohibited and may result in revocation of your posting rights - please read the FAQ for full details. Users must also abide by the Forum Guidelines at all times.
Zynda
BRFite
Posts: 1875
Joined: 07 Jan 2006 00:37
Location: J4

Re: Wuhan Coronavirus Resource Thread

Postby Zynda » 25 May 2020 19:39

Pretty long article...
Remdesivir tops list of Covid-19 drug contenders, say scientists

More than 130 drugs are under experimentation to treat Covid-19, some may have the potential to stop the virus while others may help calm overactive immune responses that damage organs, according to a tracker maintained by the Milken Institute, an independent economic think tank in the US.

With a vaccine still a long distance away, efforts to repurpose old medications used for other ailments provide hope of an early counter to Covid-19, say scientists, placing the antiviral remdesivir on top of the list of possible contenders.

As Covid-19 continues its spread -- crossing 5.2 million cases and 3,38,000 fatalities on Saturday -- several categories of drugs are under clinical trial. Of them, remdesivir, which initially went into trials for treating the deadly Ebola virus five years ago, has shown promise by modestly speeding recovery from Covid-19, experts said.

More than 130 drugs are under experimentation to treat Covid-19, some may have the potential to stop the virus while others may help calm overactive immune responses that damage organs, according to a tracker maintained by the Milken Institute, an independent economic think tank in the US, “Right now, there is only one effective approach… which is to repurpose already approved drugs for other diseases if they can be used for Covid-19. One example is remdesivir,” Ram Vishwakarma, director of the Indian Institute of Integrative Medicine, CSIR, Jammu, told PTI.

Remdesivir is helping people recover faster, and is lowering the death rate among critically ill patients, Vishwakarma said, adding that it can be life-saving.

“We do not have time to develop new drugs. New drug development takes five-10 years so we are using existing drugs and conducting clinical trials to find if any of them are effective,“ Vishwakarma said.

Some molecules available for treating diseases like HIV or other viral infections can be quickly checked against the novel coronavirus, he explained. If found effective, they can be used against Covid-19 with the appropriate approval from drug control bodies.

When drug company Gilead Sciences sought to begin clinical trials for remdesivir to treat the novel coronavirus, it immediately got approval from the US FDA.

According to Vishwakarma, the other drug showing promise is favipiravir, a broad-spectrum antiviral approved in Japan, which is also under clinical trials for its effectiveness against Covid-19.

India is also playing its role. The Indian Institute of Chemical Technology (IICT), Hyderabad, has developed the technology to make favipiravir, Council of Scientific and Industrial Research (CSIR) Director General Shekar Mande announced this month.

CSIR is conducting clinical trials for favipiravir, remdesivir and an anti-inflammatory drug called colchicine, which is commonly used to treat gout, said Vishwakarma. “A number of drug trials are happening in India, which we are doing with pharmaceutical companies,” Vishwakarma said.

Of the drugs under trial, remdesivir has shown the most promising results, agreed Subhabrata Sen, professor at the Department of Chemistry in Shiv Nadar University in Uttar Pradesh.

Sen, whose lab is involved in the discovery of biologically active molecules, told PTI that some of the drugs being tested are antivirals, and some are anti-malarials and antibiotics. Of the antivirals in the tracker list, some are new molecules under trial, whereas others are old drugs being repurposed and tested for their effectiveness against Covid-19.

Remdesivir, according to a study published in the New England Journal of Medicine in April, mimics the genetic material of the coronavirus., When the virus copies its RNA or genetic material, the drug replaces some of the pathogen’s building blocks. According to the authors of this study, the drug prevents new virus copies from being produced.

Preliminary results had shown that patients who received remdesivir had a 31 per cent faster time to recovery than those who received placebo.

However, another study published in the journal Lancet in April cautioned that interpretation of these findings is limited since the remdesivir study was stopped early after the scientists were unable to recruit enough patients due to the steep decline in cases in China.

The authors of the Lancet study concluded that more evidence from ongoing clinical trials is needed to better understand whether remdesivir can provide meaningful clinical benefit.

There are other drugs being tested too.

Some drugs developed to treat HIV, such as lopinavir and ritonavir, are also being tested to cure COVID-19, Vishwakarma said.

A study published in Lancet this month said a treatment involving a combination of the drugs interferon beta-1b, plus the antiviral combination lopinavir-ritonavir and ribavirin, is better at reducing the viral load or quantity of the virus than lopinavir-ritonavir alone.

But these, too, were early findings, observed only in patients with mild to moderate illness, so the scientists behind the study stressed the need for larger trials to examine the effectiveness of this triple combination in critically ill patients.

Another study published last month in the journal Science noted the effectiveness of two small molecule drug candidates named 11a and 11b which could block the SARS-CoV-2 M protease enzyme, which the virus uses to make copies of itself.

The molecules could stop the virus from replicating in monkey cells, and have been found safe for administration in rats and beagles, with the study concluding that both the drugs warrant further studies.

Scientists have also tested the effectiveness of therapies involving the use of antibodies that can bind to some parts of the virus, and block their entry into host cells. In a study, published last month in the journal Cell, scientists reported that antibodies derived from the immune system of the South American mammal called llamas can block the entry of the novel coronavirus into host cells.

This study found that llamas, which belong to the same category of mammals as camels, produce special kinds of antibody molecules that bind tightly to a key protein on the novel coronavirus. However, the scientists believe its efficacy is yet to be proved in human clinical trials.

Last week, scientists from the Beijing Advanced Innovation Center for Genomics at Peking University in China, revealed a new method to identify multiple antibodies from recovered Covid-19 patients.

Using a single-cell genomics method, the researchers could rapidly identify antibodies from convalescent plasma, a component of patients’ blood.

When the researchers tested these antibodies in mice, they found that some of them could neutralise the virus.

Another team from the University of Washington in the US found recently that a combination of antibodies, including those from a patient who had recovered from the 2002-03 SARS pandemic virus infection, can effectively block the novel coronavirus.

One of these molecules, named S309, showed particularly strong neutralising activity against SARS-CoV-2, they said, adding that it can act in combination with another, less potent antibody that targets a different site on the virus. However, these results too are yet to be validated in human clinical trials.

Among other therapeutics currently under trial or in use, Sen said US President Donald Trump’s “game changer” drug hydroxycholoroquine was promising “until it demonstrated serious side effects in the form of cardiovascular complications”, rendering it ineffective.

Ashokk
BRFite
Posts: 614
Joined: 11 Aug 2016 06:14

Re: Wuhan Coronavirus Resource Thread

Postby Ashokk » 25 May 2020 20:14

China decides to evacuate citizens from India amid rise in coronavirus cases
NEW DELHI: China has decided to evacuate its citizens, including students, tourists and businessmen, from India who are facing "difficulties" in the country and want to return home in the wake of the coronavirus pandemic. The Chinese embassy put out a notice on its website on Monday, asking those wanting to return home to book tickets in special flights.

disha
BR Mainsite Crew
Posts: 7381
Joined: 03 Dec 2006 04:17
Location: gaganaviharin

Re: Wuhan Coronavirus Resource Thread

Postby disha » 25 May 2020 20:51

Ashokk wrote:China decides to evacuate citizens from India amid rise in coronavirus cases


Excellent. Let Cheen go ahead and put itself in reverse lockdown mode.

disha
BR Mainsite Crew
Posts: 7381
Joined: 03 Dec 2006 04:17
Location: gaganaviharin

Re: Wuhan Coronavirus Resource Thread

Postby disha » 25 May 2020 21:24

MediaPimps in April were screaming around with testing-testing-testing and now one must wonder why that frenzied chorus has died down?

What happened? It is not easy to develop virus testing kits and processes. It is not something like from holly-bolly-tolly-wood movies where you scan the retina of the eye (or a sweat swipe) and the all the virus genealogy tumbles out into a 3D graphical interface.

Here is the true story of the immense effort and ingenuity of the Indian medical professions and yes the PMO itself (there is somebody called Modi in the PMO who seems to drive lot of things):

https://www.hindustantimes.com/india-news/in-india-s-covid-19-testing-strategy-a-hard-push-from-pm-modi-and-a-dose-of-reality/story-OdltrmDPeTD4BRPUEM0qMP.html

Please do read it in full. Particularly the part where a testing kit and process has to be set up at a district level.

Added later: Will let the readers figure out which machines are being talked about here:

With supplies of these machines, it would be possible to have Covid-19 testing capacities in districts with no capacity for carrying out the RT-PCR tests, or reverse transcriptase polymerase chain reaction test that is considered the gold standard for detecting Sars-Cov-2 virus.


So where are the mediapimps now? Why cannot they talk about the spectacular success of testing strategy in India?

mappunni
BRFite
Posts: 231
Joined: 14 Jul 2017 19:07

Re: Wuhan Coronavirus Resource Thread

Postby mappunni » 25 May 2020 21:37

Ashokk wrote:China decides to evacuate citizens from India amid the rise in coronavirus cases


Am I the only one reading between the lines?

CRamS
BRF Oldie
Posts: 6794
Joined: 07 Oct 2006 20:54
Contact:

Re: Wuhan Coronavirus Resource Thread

Postby CRamS » 26 May 2020 00:21

mappunni wrote:
Am I the only one reading between the lines?


You mean Chincoms upping the ante with India? Possible. Sad part is that if they do that, India is on its own. US will make some noises, but nothing beyond that. Hope our military planners and govt are prepared.

Coming to the Corona virus itself, its seem India is now the 5th worst affected in terms of # of cases according to TimesNow. This is staggering. And while the recovery rate looks healthy at 42+%, still the rising # of cases is a cause for worry. Not sure what the Indian govt can do. Damned if you do (lock down), damned if you don't. Among all jobs in the world, being the PM of India is the most challenging of them all at this time.

yensoy
BRFite
Posts: 1750
Joined: 29 May 2002 11:31
Location: USA

Re: Wuhan Coronavirus Resource Thread

Postby yensoy » 26 May 2020 00:42

mappunni wrote:
Ashokk wrote:China decides to evacuate citizens from India amid the rise in coronavirus cases

Am I the only one reading between the lines?


Very unlikely this has anything to do with the border. All sorts of countries are evacuating citizens from India with a lot of flights - but this doesn't make news. You can look on flightradar24 to see incoming passenger flights on international airlines and draw your conclusions. Now China joins this list. It has to be an evacuation flight as long as scheduled flights don't start, and they will in a few weeks but we are talking about China here.

Ambar
BRFite
Posts: 1377
Joined: 12 Jun 2010 09:56
Location: Weak meek unkil Sam!

Re: Wuhan Coronavirus Resource Thread

Postby Ambar » 26 May 2020 02:03

CRamS wrote:
mappunni wrote:
Am I the only one reading between the lines?


Coming to the Corona virus itself, its seem India is now the 5th worst affected in terms of # of cases according to TimesNow. This is staggering. And while the recovery rate looks healthy at 42+%, still the rising # of cases is a cause for worry. Not sure what the Indian govt can do. Damned if you do (lock down), damned if you don't. Among all jobs in the world, being the PM of India is the most challenging of them all at this time.


You need to look at cases/1M population. With 1.33 billion people and the Chinese as usual hiding their numbers, we will have a lot more cases per day compared to nations with smaller population.

IndraD
BRF Oldie
Posts: 7267
Joined: 26 Dec 2008 15:38
Location: भारत का निश्चेत गगन

Re: Wuhan Coronavirus Resource Thread

Postby IndraD » 26 May 2020 03:51

https://www.theguardian.com/world/2020/ ... oronavirus
How Japan contained nCV without lockdown
(with 3 Cs: avoid crowd, confined places & contact)

mappunni
BRFite
Posts: 231
Joined: 14 Jul 2017 19:07

Re: Wuhan Coronavirus Resource Thread

Postby mappunni » 26 May 2020 05:49

Ambar wrote:
CRamS wrote:
Coming to the Coronavirus itself, it seems India is now the 5th worst affected in terms of # of cases according to TimesNow. This is staggering. And while the recovery rate looks healthy at 42+%, still the rising # of cases is a cause for worry. Not sure what the Indian govt can do. Damned if you do (lockdown), damned if you don't. Among all jobs in the world, being the PM of India is the most challenging of them all at this time.


You need to look at the cases/1M population. With 1.33 billion people and the Chinese, as usual, hiding their numbers, we will have a lot more cases per day compared to nations with smaller populations.


When has ChiCom provided the real numbers, be it economic or otherwise? It has been very hard to get any facts coming from the ChiComs even in the Pandemic situation. Watching Epoch times, they say there is the second Corona outbreak in two Northern provinces and is much harder to detect until the person ends up gasping for air! Apparently the virus has mutated into 30 different ones now.

sajo
BRFite
Posts: 224
Joined: 01 Mar 2019 17:01

Re: Wuhan Coronavirus Resource Thread

Postby sajo » 26 May 2020 11:58

So the enemy is at the gates, or rather, a few hundred feet from my apartment complex' gate. A large colony with many wings had a positive case, guy apparently also had a functioning restaurant delivery business. The Pune Municipal Corporation and Police have sealed the building (all wings) totally, with no movement permitted in and out of the gates for 14 days. Arogya Setu shows nothing though, its been a couple of days so I dont think its delays in updating the data. How exactly does the app work? If they guy does not have it on his phone, nobody around him will be updated?

vijayk
BRF Oldie
Posts: 4517
Joined: 22 Jun 1999 11:31

Re: Wuhan Coronavirus Resource Thread

Postby vijayk » 26 May 2020 18:46

https://www.ibtimes.com/coronavirus-tre ... ls-2982390
India expands use of Hydrochloroquine

They see benefit of using this as preventive not as a cure ...

srai
BRF Oldie
Posts: 4680
Joined: 23 Oct 2001 11:31

Re: Wuhan Coronavirus Resource Thread

Postby srai » 27 May 2020 06:08

May 27, 2020
United States

Coronavirus Cases: 1,725,499
Deaths: 100,573
Recovered: 478,341

sudarshan
BRF Oldie
Posts: 2296
Joined: 09 Aug 2008 08:56

Re: Wuhan Coronavirus Resource Thread

Postby sudarshan » 27 May 2020 06:34

US COVID daily deaths as reported day-by-day to worldometer. What the *hic* are they doing to the data, that it's behaving like this? Reporting delays are one possibility, but that regular sawtooth cycle is puzzling.

April 15th was the day the reporting criterion changed. Like I said before, the actual deaths curve had started falling well below the prediction before that date, then the new criterion changed things.

Image

sudarshan
BRF Oldie
Posts: 2296
Joined: 09 Aug 2008 08:56

Re: Wuhan Coronavirus Resource Thread

Postby sudarshan » 27 May 2020 06:49

Sweden finished one round of antibody testing, and found that about 7% of Stockholm had been infected. Lots of press headlines, about how the herd immunity strategy failed, and how long a way it is to the herd immunity threshold of 60%.

The HIT is not set in stone, 60% HIT is based on an extremely simple infection model with an estimated R0 of 2.4. Putting in some realistic assumptions (conservative) about inhomogenities, the HIT comes down to the 10% to 20% range. If the inhomogenity assumptions are not so conservative (more in line with observed CV parameters of around 3.1 to 3.2 for COVID) the HIT comes down below 10% even, with the same R0 of 2.4. In a country with a low population density to begin with, R0 might not even be as high as 2.4.

If after so many months of an epidemic, lacking lockdowns, the infected fraction is still as low as 7% in an acknowledged hotspot, it could be time to reevaluate the assumption of "60% HIT." Holding that number as a fixed, unquestionable value and arguing to prolong lockdowns so long as it is not reached, might not be a viable strategy.

williams
BRFite
Posts: 424
Joined: 21 Jun 2006 20:55

Re: Wuhan Coronavirus Resource Thread

Postby williams » 27 May 2020 07:16

sudarshan wrote:US COVID daily deaths as reported day-by-day to worldometer. What the *hic* are they doing to the data, that it's behaving like this? Reporting delays are one possibility, but that regular sawtooth cycle is puzzling.

April 15th was the day the reporting criterion changed. Like I said before, the actual deaths curve had started falling well below the prediction before that date, then the new criterion changed things.

Image


Sawtooth cycle is because of underreporting on weekends.

disha
BR Mainsite Crew
Posts: 7381
Joined: 03 Dec 2006 04:17
Location: gaganaviharin

Re: Wuhan Coronavirus Resource Thread

Postby disha » 27 May 2020 07:35

^Thanks for the update.

Initially when the epidemiology and the outcome and the 'treatment' of the virus was unknown, it made sense to go into full lockdown and extend that lockdown. It also gave time to set up the infrastructure. For example the testing infrastructure and using HCQ as prophylaxis.

From this point onwards, it does not make sense to go for general lockdown and it definitely does not make sense to just look at the raw positive numbers and the raw death numbers.

Dr. Shamika Ravi is arguing for 'smart lockdown' based on the epidemiology of the virus https://t.co/GigW4eScjm?amp=1

In the early days of the pandemic, limited data availability led the first generation, epidemiological models, to predict that hundreds of millions would be infected with the virus, and millions of lives lost. Fortunately, the reality so far has turned out to be very different.


All the predictions are based on epidemiological models and the models do not account for 'local' distribution. For example, the population density of New York is not comparable to the population density of Texas. A county within California cannot be compared to another county. Similarly in India a district cannot be compared to another. On top of it, the movement of people within a bound geographical area is not completely free and completely random.

On top of it, cultural patterns of contact and crowd need to be modeled.

In fact, nuclear physicists must be brought in to model the epidemiology and develop software models running on supercomputers based on the models developed by nuclear physicists.

research based on the previous Severe Acute Respiratory Syndrome (Sars) epidemic in 2003 has shown that there is a great deal of variability in individual infectiousness. For example, research on Sars epidemic from Singapore revealed that the majority (approximately 73%) of the cases were mildly infectious; in other words, they had an R0 of less than one, while a small proportion of them (approximately 6%) was highly infectious or “super-spreaders” with an R0 > eight.


In essence, identify the superspreaders and isolate them. For example, Thookers and Thooblighis tried to be super spreaders. And they were isolated successfully in some parts of the country and due to political implications, they became hyper spreaders in other parts of the country.

Data point from twitter

Prof Shamika Ravi
@ShamikaRavi
·
17h
Solution to COVID situation in MH cannot be - "But GJ is worse."

1) Case load: 36% (MH) vs. 10% (GJ)
2) New cases: 2500 (MH) vs. 400 (GJ)
3) Death/million: 13.89 (MH) vs. 13.93 (GJ)
4) Cases/100 tests: 13.25% (MH) vs. 7.76%(GJ)
Situation is bad in GJ too, but MH is worse. Focus!

Shivam Singhania
@ShivmSinghania
Replying to
@ShamikaRavi
+ 1) deaths are stabilising in GJ, though still high
2) spread is more concentrated, 80% active cases in Ahmd
3) total and active cases similar to DL with 3x more pop.
4) recovery rate close to 50%, most districts 60-70%, unlike 30% for MH
5) active case load 9% vs 44% MH


The concentration of active cases in Ahmedabad is concentrated further into specific wards. It is not Islamophobic to point out that those wards have the highest concentration of Muslims and their cultural practices are contributing both to higher caseloads and higher death rate.

Given the above data points, one thing is certain: Current epidemiological models out there are incomplete and very error prone

sudarshan
BRF Oldie
Posts: 2296
Joined: 09 Aug 2008 08:56

Re: Wuhan Coronavirus Resource Thread

Postby sudarshan » 27 May 2020 07:54

williams wrote:Sawtooth cycle is because of underreporting on weekends.


Could you look at the date range from April 28th (Tue) to May 10th (Sun)? There's a distinct drop in numbers as the week progresses, then back to a high value the next week. For the observed pattern in that date range, they got to be underreporting a bit more every day, as the week progresses, with max. underreporting on Sat/Sun.

EDIT: If there was underreporting Fri/Sat/Sun and those were made up on Mon/Tue/Wed that might make sense (delayed reporting).

hanumadu
BRF Oldie
Posts: 4709
Joined: 11 Nov 2002 12:31

Re: Wuhan Coronavirus Resource Thread

Postby hanumadu » 27 May 2020 08:39

sudarshan wrote:Sweden finished one round of antibody testing, and found that about 7% of Stockholm had been infected. Lots of press headlines, about how the herd immunity strategy failed, and how long a way it is to the herd immunity threshold of 60%.


While Sweden might not have an official lockdown, its people were following social distancing and curbing activities that they would normally do. According to reports, its economy is doing no better than others.

hanumadu
BRF Oldie
Posts: 4709
Joined: 11 Nov 2002 12:31

Re: Wuhan Coronavirus Resource Thread

Postby hanumadu » 27 May 2020 10:37

sudarshan wrote:
The HIT is not set in stone, 60% HIT is based on an extremely simple infection model with an estimated R0 of 2.4. Putting in some realistic assumptions (conservative) about inhomogenities, the HIT comes down to the 10% to 20% range. If the inhomogenity assumptions are not so conservative (more in line with observed CV parameters of around 3.1 to 3.2 for COVID) the HIT comes down below 10% even, with the same R0 of 2.4. In a country with a low population density to begin with, R0 might not even be as high as 2.4.


The biggest factor affecting inhomogeneity seems to be the velocity of people or people moving about and interacting with each other. By the very definition lock downs and social distancing increases inhomogeneity but free movement of people increases inhomogeneity. So how can we consider HIT during a lockdown and social distancing phase as the real HIT?

sudarshan
BRF Oldie
Posts: 2296
Joined: 09 Aug 2008 08:56

Re: Wuhan Coronavirus Resource Thread

Postby sudarshan » 27 May 2020 10:39

Disha, yes, that's what I've been saying, the initial lockdown was probably inevitable, but now it needs to be driven based on empirical data (not modeled data).

hanumadu wrote:
sudarshan wrote:Sweden finished one round of antibody testing, and found that about 7% of Stockholm had been infected. Lots of press headlines, about how the herd immunity strategy failed, and how long a way it is to the herd immunity threshold of 60%.


While Sweden might not have an official lockdown, its people were following social distancing and curbing activities that they would normally do. According to reports, its economy is doing no better than others.


The point is, public policy should not be driven by a rigid assumption (such as "HIT=60%"), especially when that assumption comes from a naive, first-order mathematical model. Assumptions need to be revised based on fresh data. I do see some acknowledgment of that fact from the scientists, but the press seems stuck on old assumptions. And it's looking like the press is what drives policy.

Mathematical modeling was fine when the disease was totally unknown, that is not the case now. Being stuck on some number from a naive model and holding that as a metric to be achieved, is not right. Targeted lockdowns based on empirical data make more sense.

sudarshan
BRF Oldie
Posts: 2296
Joined: 09 Aug 2008 08:56

Re: Wuhan Coronavirus Resource Thread

Postby sudarshan » 27 May 2020 10:55

hanumadu wrote:
sudarshan wrote:
The HIT is not set in stone, 60% HIT is based on an extremely simple infection model with an estimated R0 of 2.4. Putting in some realistic assumptions (conservative) about inhomogenities, the HIT comes down to the 10% to 20% range. If the inhomogenity assumptions are not so conservative (more in line with observed CV parameters of around 3.1 to 3.2 for COVID) the HIT comes down below 10% even, with the same R0 of 2.4. In a country with a low population density to begin with, R0 might not even be as high as 2.4.


The biggest factor affecting inhomogeneity seems to be the velocity of people or people moving about and interacting with each other. By the very definition lock downs and social distancing increases inhomogeneity but free movement of people increases inhomogeneity. So how can we consider HIT during a lockdown and social distancing phase as the real HIT?


Inhomogeneity implies *differences between people for the same parameter*. Social distancing decreases inhomogeneity - everybody stays away from everybody else, everybody does the same thing as everybody else (homogeneous). When people move freely, that's when inhomogeneity matters, because then some people move a lot more than others, etc.

In any case, that is not the only factor affecting inhomogeneity, and whether it is the "biggest" factor is also debatable. There is still inhomogeneity based on developed viral load upon infection, and inhomogeneity based on individual susceptibility to the disease. In India there is also inhomogeneity based on propensity to spit and cough deliberately. This is what I was saying in my earlier post.

So the idea is - estimate the non-lockdown HIT from the model. Compare with the measured infection rate (with or without lockdown - irrelevant - since this is measured data - antibody testing). If the measured rate is higher than the non-lockdown HIT estimate, one can reasonably suppose that there will be little further spread when the lockdown is removed. If not, need to watch out.

But I'm saying - forget these numbers, go with observed empirical data (not deliberately expose any part of the population to get that data, but going by what is available). So forget that 60% HIT also, because even mathematically, there are reasons why it could be a lot lower than that, even with the same R0. That empirical data would be like - slope of actual daily deaths curve, or slope of ICU admissions curve. Lot more practical than mathematical models.

vijayk
BRF Oldie
Posts: 4517
Joined: 22 Jun 1999 11:31

Re: Wuhan Coronavirus Resource Thread

Postby vijayk » 27 May 2020 20:45



The Dr who "debunked" HydroxyChloroquine got a $2500,000 grant from the maker of Remdisivir.

Ambar
BRFite
Posts: 1377
Joined: 12 Jun 2010 09:56
Location: Weak meek unkil Sam!

Re: Wuhan Coronavirus Resource Thread

Postby Ambar » 28 May 2020 00:53

Is there a dashboard that tracks daily increase in cases and deaths by state for India similar to what we have for US ? The Ministry of Health dashboard just gives total numbers without day over day comparison. The last 24 hrs have seen the highest daily rise in cases and deaths in India at 7293 and 190 deaths.

Krita
BRFite
Posts: 169
Joined: 23 Jul 2009 13:33

Re: Wuhan Coronavirus Resource Thread

Postby Krita » 28 May 2020 01:02

Ambar wrote:Is there a dashboard that tracks daily increase in cases and deaths by state for India similar to what we have for US ? The Ministry of Health dashboard just gives total numbers without day over day comparison. The last 24 hrs have seen the highest daily rise in cases and deaths in India at 7293 and 190 deaths.

https://www.covid19india.org/
https://covidindiastats.com/
https://mobile.twitter.com/WOB5555
http://covidindiaupdates.in/epicurve_state.php

disha
BR Mainsite Crew
Posts: 7381
Joined: 03 Dec 2006 04:17
Location: gaganaviharin

Re: Wuhan Coronavirus Resource Thread

Postby disha » 28 May 2020 01:35

Ambar wrote:Is there a dashboard that tracks daily increase in cases and deaths by state for India similar to what we have for US ? The Ministry of Health dashboard just gives total numbers without day over day comparison. The last 24 hrs have seen the highest daily rise in cases and deaths in India at 7293 and 190 deaths.


Yes, Shamika Ravi's tweets have the dashboards. For example:

Image and this

Image

disha
BR Mainsite Crew
Posts: 7381
Joined: 03 Dec 2006 04:17
Location: gaganaviharin

Re: Wuhan Coronavirus Resource Thread

Postby disha » 28 May 2020 01:39

^It is evident where the #thookers and #thooblighis caused damage. Instead of blaming the government, given the above data, coronavirus impacted people must sue the #thookers and #thooblighis.

Also, why is the CFR in TN lower than MH and GJ?
Last edited by disha on 28 May 2020 01:46, edited 1 time in total.

IndraD
BRF Oldie
Posts: 7267
Joined: 26 Dec 2008 15:38
Location: भारत का निश्चेत गगन

Re: Wuhan Coronavirus Resource Thread

Postby IndraD » 28 May 2020 01:46

Oxford scientist insults other vaccine teams https://edition.cnn.com/2020/05/27/heal ... index.html
Oxford's Sarah Gillbert bragging about her vaccine not going down well
Hill, the Oxford scientist, has several arguments about why he thinks his vaccine is more promising than the others currently in human clinical trials.
First, he cites his team's many years of research on the technology used in their Covid vaccine.
The Oxford vaccine uses what's called an adenovirus vector. Adenoviruses cause the common cold, but in this case, the adenoviruses are weakened and modified to deliver genetic material that codes for a protein from the novel coronavirus. The body then produces that protein and, ideally, develops an immune response to it.
Hill and his colleagues have been working on adenovirus vaccines for nearly 20 years, and it's been used on thousands of study subjects in vaccines targeting more than 10 different diseases, according to the website for the Oxford vaccine.
Despite all this research, none of the Oxford vaccines has made it on the market, Hill said.
Still, Hill told CNN in the May 19 interview that his vaccine, plus one in China that also uses an adenovirus vector, are "the front runners" among the vaccines in clinical trials.
Hill then proceeded to disparage other teams' vaccines -- a highly unusual and aggressive move.
The four US vaccine candidates use a different technology -- or vaccine "platform" -- than Oxford.
Two of them, Moderna and Pfizer, use RNA vaccines, which inject a piece of genetic material from the novel coronavirus into human cells to stimulate immunity.
Hill described RNA vaccines as merely "noise from the new boys."
A Harvard University blog describes it differently.
"Compared to previous vaccines, this method is more robust, more versatile, and yet, equally efficient," according to the blog, which notes that the Bill & Melinda Gates Foundation invested $53 million in a German biotech company that specializes in RNA vaccines.
Hill was particularly disparaging of Moderna, which he said has "weird and wonderful technology." When asked what he meant by "wonderful," Hill said, "I was being sarcastic."
"They've got an unproven technology," he said.
CNN asked Moderna for its response, as well as Pfizer.
"Our only competitors in this race are the virus and the clock. We are rooting for multiple vaccines to succeed because we believe no manufacturer can make enough doses for the planet," according to the Moderna statement.
In March, Pfizer CEO Dr. Albert Bourla put out a five-point plan for companies to "work as one team across the industry."
"Our industry peers, the other pharmaceutical and biotechnology companies as well as health authorities, have come together like never before. We're acutely aware that we are all on the same side, and COVID-19 and other diseases are the enemy," Pfizer spokeswoman Amy Rose wrote in an email to CNN.
Hill also took a jab at Inovio, a US vaccine maker in clinical trials, saying "they can't scale up to get into phase three," clinical trials.
To take on the coronavirus, US vaccine makers consider an unprecedented strategy: working together
To take on the coronavirus, US vaccine makers consider an unprecedented strategy: working together
Inovio's technology uses a brief electrical pulse to deliver plasmids, or small pieces of genetic information, into human cells. Inovio says those cells then produce the vaccine, which leads to an immune response.
Jeff Richardson, a spokesman for the company said that "our competition is the virus, not other companies. There needs to be three or four winners to vaccinate the world. Most likely, there will be a number of vaccines that make it, and that's a good thing."
As for the four Chinese companies in clinical trials with a potential Covid vaccine, Hill said "they have a problem."
For a vaccine clinical trial to be successful, there needs to be sufficiently high levels of the virus circulating in the community. If there isn't enough virus around, it will be impossible to tell if the vaccine protected the study subjects, or if they were just never exposed to the virus.
"There's no Covid left in China. They can't finish," Hill said.
There is still a bit of Covid left in China, with a few dozen cases left, according to the latest briefings by the nation's National Health Commission. While this is likely not enough for a full-scale clinical trial, the researchers could conduct trials in other countries where the vaccine is still circulating more widely.

IndraD
BRF Oldie
Posts: 7267
Joined: 26 Dec 2008 15:38
Location: भारत का निश्चेत गगन

Re: Wuhan Coronavirus Resource Thread

Postby IndraD » 28 May 2020 01:50

China claims to have tested 7 million people in less than a week in Wuhan , it is using batch testing method for speed. https://www.nytimes.com/2020/05/26/worl ... tests.html

IndraD
BRF Oldie
Posts: 7267
Joined: 26 Dec 2008 15:38
Location: भारत का निश्चेत गगन

Re: Wuhan Coronavirus Resource Thread

Postby IndraD » 28 May 2020 02:00

HCQ continues to be smeared, Gielad making kill though there is no evidence its drug Remdesivir works against nCV , a large librandu lobby in medical journal and msm are spearheading smear campaign against HCQ cos Trump stood by it.

WHO stops HCQ trials https://www.theguardian.com/world/2020/ ... fety-fears

Remdesivir approved in UK despite lack of evidence https://www.bbc.co.uk/news/health-52805828

France bans use of HCQ https://www.nytimes.com/2020/05/27/worl ... nk-af3ff1d

DavidD
BRFite
Posts: 918
Joined: 23 Jun 2010 04:08

Re: Wuhan Coronavirus Resource Thread

Postby DavidD » 28 May 2020 04:12

IndraD wrote:
nam wrote:Some good news on vaccine development.

6 prototype DNA vaccine developed, showed remarkable efficiency in monkeys. All 6 developed immune protein and none of the monkeys had lung infection post vaccination. The ones which were not vaccinated, developed lung infection.

Higher the level of immunity protein, lower was the viral load.

https://www.bidmc.org/about-bidmc/news/2020/05/covid-19-vaccine


at the moment there are 240 vaccines in pipeline, each at different stage of development. Two of them quite talked about at the moment are: Oxford & Moderna. Oxford is into second phase of trial and Moderna will now recruit for phase I trial , they had promising results in Macac monkeys. Oxford one prevented pneumonia in monkeys but couldn't prevent infection.
India has 14 vaccines in development process.
http://timesofindia.indiatimes.com/arti ... aign=cppst
they yet have to enter a trial phase but hope to develop a vaccine within 12 months, WHO has enlisted 3 vaccine companies of India.

It is surprising China in spite of harbouring virus since August hasn't developed a vaccine yet! Their vaccine Ad5-nCoV is a genetically engineered vaccine candidate with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein, which intends to be used to prevent the disease caused by Covid-19. Phase I trial saw 108 inoculated with vaccine , while they produced cell & antibody mediated immunity, every patient developed fever, headache, chills :eek:

Such is the pressure on the govt, US has paid $1 billion to Astra Zenca co partnering Oxford vaccine in advance for 100 million shots. UK already is producing 30 million vaccine along with trial as vulnerable must be vaccinated before winter. From buzz US wants to give both (Moderna & Oxford) shots to its people.


The Chinese vaccine is the farthest along, the only one that has published peer-reviewed phase I results. It uses a very similar technique as Oxford, using an Adenovirus as the vector. Since it uses a live virus that's well known to cause the common cold as the vector, its most common side effect is those of a common cold, which I imagine will be very similar with the Oxford vaccine.

I don't know enough about virology and immunology to know the difference between the COVID spike protein inserted into the Adenovirus by each team. It's interesting though that 6/6 vaccinated monkeys in animal studies with the Oxford vaccine contracted COVID (compared to 3/3 unvaccinated monkeys), but only 1/8 of ferrets with the Chinese vaccine contracted it (compared to 7/8 in unvaccinated ferrets).

IndraD wrote:HCQ continues to be smeared, Gielad making kill though there is no evidence its drug Remdesivir works against nCV , a large librandu lobby in medical journal and msm are spearheading smear campaign against HCQ cos Trump stood by it.

WHO stops HCQ trials https://www.theguardian.com/world/2020/ ... fety-fears

Remdesivir approved in UK despite lack of evidence https://www.bbc.co.uk/news/health-52805828

France bans use of HCQ https://www.nytimes.com/2020/05/27/worl ... nk-af3ff1d


Actually, if you read the Remdesivir trial closely, you'll see that not only is there a pretty strong trend toward improving mortality among all patients, a subgroup analysis would show that the lack of efficacy is primarily in the sickest groups. Take a look at figure 2 in the Remdesivir article. It's not unreasonable to think that if the medication is started early, it could prevent quite a few deaths.

I'm not trying to rag on HCQ, I suspect it can show an efficacy when used early as well, but there's simply no scientifically significant data to prove that thus far.

Image

IndraD
BRF Oldie
Posts: 7267
Joined: 26 Dec 2008 15:38
Location: भारत का निश्चेत गगन

Re: Wuhan Coronavirus Resource Thread

Postby IndraD » 28 May 2020 04:43

Can you please provide link to the article/paper you have quoted graphs from please? ^^

mukkan
BRFite -Trainee
Posts: 43
Joined: 01 May 2020 21:26

Re: Wuhan Coronavirus Resource Thread

Postby mukkan » 28 May 2020 08:23

Anti-HCQ Paper in The Lancet Uses Fake Data
https://defyccc.com/anti-hcq-paper-in-t ... ated-data/

srai
BRF Oldie
Posts: 4680
Joined: 23 Oct 2001 11:31

Re: Wuhan Coronavirus Resource Thread

Postby srai » 28 May 2020 14:44

Very powerful evocative interactive!

https://www.nytimes.com/interactive/202 ... 00000.html

chetak
BRF Oldie
Posts: 22438
Joined: 16 May 2008 12:00

Re: Wuhan Coronavirus Resource Thread

Postby chetak » 28 May 2020 23:53

For population control or what :mrgreen:


Image

disha
BR Mainsite Crew
Posts: 7381
Joined: 03 Dec 2006 04:17
Location: gaganaviharin

Re: Wuhan Coronavirus Resource Thread

Postby disha » 29 May 2020 01:25

DavidD wrote:
The Chinese vaccine is the farthest along, the only one that has published peer-reviewed phase I results.


Of course! You had like 2 or 3 months headstart over others? That shows.

...Since it uses a live virus that's well known to cause the common cold as the vector, its most common side effect is those of a common cold, which I imagine will be very similar with the Oxford vaccine...


Are you a virologist experienced in vaccine development to comment confidently as above? I would believe that the body to develop antibodies requires a spike protein from coronavirus. And this spike protein will cause similar side effects as that of the WuhanVirus as the body defenses start building up.

If the above is not the case and if it is just like you said above, then why is not China going in for mass immunization and just get to Phase 4. Skip Phase 2 and 3 as well.

I don't know enough about virology and immunology to know the difference between the COVID spike protein inserted into the Adenovirus by each team. It's interesting though that 6/6 vaccinated monkeys in animal studies with the Oxford vaccine contracted COVID (compared to 3/3 unvaccinated monkeys), but only 1/8 of ferrets with the Chinese vaccine contracted it (compared to 7/8 in unvaccinated ferrets).


Maybe by accident an attenuated WuhanVirus was injected. How do you know that was not the case? Do you trust the data provided by the Communist dictatorship in China?

I'm not trying to rag on HCQ, I suspect it can show an efficacy when used early as well, but there's simply no scientifically significant data to prove that thus far.


But there is enough scientific data on the Chinese vaccine for WuhanVirus!

Studies after studies show that HCQ is safe prophylaxis against WuhanVirus and it can be provided to frontline as well as certain segments of immuno-compromised population or population with co-morbidities.

Just that China will not talk about HCQ since the honour and dignity will be accorded to India for restarting the world economy while internally it might even be giving out HCQ as prophylaxis and in the meantime again influencing WHO to tell lies.

I will leave it up to you to dig the scientific details.

IndraD
BRF Oldie
Posts: 7267
Joined: 26 Dec 2008 15:38
Location: भारत का निश्चेत गगन

Re: Wuhan Coronavirus Resource Thread

Postby IndraD » 29 May 2020 02:38

mukkan wrote:Anti-HCQ Paper in The Lancet Uses Fake Data
https://defyccc.com/anti-hcq-paper-in-t ... ated-data/

many thanks, very interesting read! While most of the allegations are based on assumptions and what ifs...it sounds resoundingly correct! I will post it in full
Good news: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis, Harvey A Risch, May 27, 2020, American Journal of Epidemiology

Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multicomorbidities, with estimated proportion diagnosed with cardiac arrhythmias attributable to the medications 47/100,000 users … These medications need to be widely available and promoted immediately for physicians to prescribe.

The rest of the post discusses a fraudulent paper (Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Mehra et al., May 22, 2020, The Lancet), based on Surgisphere’s fake data.

Surgisphere Corporation is fraud. Some of its services are being used for COVID-19 diagnostics and/or clinical decisions: QuartzClinical, COVID-19 Decision Support Tools (Rapid Triage, Severity Scoring, Diagnosis, Mortality Risk), Surgical Outcomes Collaborative analytics platform.
This anti-HCQ Lancet paper claims: “We included all patients hospitalised between Dec 20, 2019, and April 14, 2020, at hospitals participating in the registry” with COVID-19 and records of death or discharge. 671 hospitals from six continents allegedly provided their data for this database. The US hospitals were allegedly “selected to match the epidemiological characteristics of the US population”. In this great database, the authors have found 96,032 hospitalized patients with COVID-19, including 14,888 treated with HCQ or CQ with either Azithromycin (AZM) or Clarithromycin.

At this point, one would ask: Who has a database with detailed information on 96,000 patients? What about privacy laws? What about network security and data compatibility? Is Surgisphere a three-letter agency with such unrestricted global access? No, this is a one-man fraud. Paper’s second author is the man. There is no patients’ database and any raw data was fabricated or did not exist at all.

Some of the many mysteries in the alleged data:

The population data is very homogeneous, almost the same across the six continents – this is highly unlikely. For example, the patients with qSOFA < 1 are 82.6% in Europe and North America (what a coincidence!), and 82.7% in South America (Table S3).
The study data shows only 42% of patients (6,221 out of 14,888) in the treatment groups received HCQ+”macrolide”. However, it is widely known that almost all people treated with HCQ or CQ received HCQ+AZM.
In the study data for North America, 35% of patients (3,415) received CQ and 65% of patients (6,462) received HCQ. However, it is widely known that, outside of China, CQ was used significantly less than HCQ. The actual ratio is closer to 1:99 than to 35:65.
All patients treated with CQ/HCQ received antibiotics, almost always AZM. In the study, 32% of the North American patients received no “microlide” (Appendix, Table S3). Do peer reviewers really believe that almost a third of patients hospitalized with respiratory infection received immunosuppressives without antibiotics?
Tweets from an Australian MD & PhD helped explain some of the mystery. Not only is the data fake, but the database itself, Surgical Outcomes Collaborative, is fake as well. Here are some of the many red flags:

the study says that they received data from 600 hospitals up to mid-April, and it was published end-May. This is impossible. If you have ever collected clinical research data you will know how impossible it is.

… you need ethical approval, suitable web servers set up, access set up for each hospital (and ideally each worker). This is what the authors say happened – they say they questioned existing repositories

I’m sorry but these don’t exist. Repositories do exist that maintain some of this data but it is mostly unlinked, relies on it being filled in correctly and exists on different systems that don’t talk to each other. …

… for each hospital system providing access you have to go through a complex ethics approval system (otherwise your hospital has just given your personal data to some strangers). …

An ethics approval of this magnitude would take months but it would take even longer to get the system up and running to allow secure access to hospital data systems externally. IT JUST DOES NOT HAPPEN.

The thread continues. The doctor takes note that the patients’ data matches, almost perfectly, on 23 factors.

This is pretty much statistically impossible, and they are claiming that they got this matching in 7000 patients out of a pool of 96000 patients for which they received high quality information from 671 hospitals. Nope. Sorry, the data is too “clean”.

And

So, this group are telling us that, not only have they got access to 671 hospital clinical record systems but (and this is a problem) … They have access to all the pathology providers linked to those 671 hospitals and THEY CAN DATA LINK THE PATIENT RECORDS. Not a chance.

This didn’t happen, and if it did it would be a massive privacy scandal. There would be serious financial and potentially criminal repercussions

So, either this data is completely fabricated -or- The authors have been able to overcome impossible hurdles of data sharing and probably broken a number of laws in the process.

Surgisphere has only a few employees, hired since February 2020. They did not overcome any hurdles.

This Lancet paper also heavily promotes Surgical Outcomes Collaborative, the fake database from which the data has been obtained. The “Collaborative” is owned by the Surgisphere Corporation. Sapan S. Desai, one of the paper’s authors, is a Surgisphere founder (disclosed) and CEO (not disclosed). The “Collaborative”, which was unknown before May 2020, is mentioned by name seven times in the paper. Two paragraphs (~500 words) are used as Collaborative advertisement: “a cloud-based health-care data analytics platform that includes specific modules for data acquisition, data warehousing, data analytics … A manual data entry process is used for quality assurance and validation to ensure that key missing values are kept to a minimum … ensures compliance with the US Food and Drug Administration (FDA) guidance on real-world evidence … data are collected through automated data transfers that capture 100% of the data from each health-care entity at regular, predetermined intervals … the standard operating procedures in place for each of the four ISO 9001:2015 and ISO 27001:2013 certified features of the registry … Collection of a 100% sample from each health-care entity is validated against financial records … capturing all-comer data and consecutive patient enrolment by capturing 100% of the data within electronic systems … compliant with the US Agency for Healthcare Research and Quality guidelines for registries …”.

None of this is true.

Surgisphere Corporation

Surgisphere’s website does not display its directors or executives, other than its founder-CEO Sapan S Desai (SSD) (About)
The website surgisphere.com is excluded from Archive.org – a sure sign that the company does not want people to know what it looked like in the past.
SSD worked in Surgisphere only part-time until February 2020, according to his profile in LinkedIn. His last full-time position was “Full-time clinical vascular surgeon, Medical Director of Surgical Quality, and Director of CME at Northwest Community Hospital” in Arlington Heights, IL
LinkedIn also shows profiles of four other employees. The three employees visible to me were hired in February 2020 or later. All of them live in different areas of the USA.
The address of Surgisphere is a private house in Palatine, IL, probably SSD’s home. (Buzzfile)
Surgisphere is not listed as a tenant at the address listed on its websites (875 N Michigan Ave, 31st Floor, Chicago, IL 60611)
In other words, Surgisphere Corporation existed mostly on paper, until February 2020, when its founder decided to cash out on the COVID-19 epidemic. Its software and services are vaporware.

The Surgical Outcomes Collaborative (database)

The Surgical Outcomes Collaborative has its own website surgicaloutcomes.com. Surgisphere markets it as an analytics platform, not a database. Nowhere does it claim possession of or access to patients’ information from multiple hospitals. Further, its website is a re-branding of another company’s website vascularoutcomes.com. Another Surgisphere’s website is quartzclinical.com.

Clarithromycin

This Lancet paper does not break down results between AZM and Clarithromycin, nor do they explain why they selected Clarithromycin, so I will. Clarithromycin has harmful interactions with CQ and HCQ (unlike AZM), and Clarithromycin is a strong QT prolonger, (unlike AZM, which is a mild one). This is why physicians did not use Clarithromycin with HCQ as a COVID-19 treatment. I could only find a couple of single patient reports of combining Clarithromycin with CQ. The authors included Clarithromycin in the paper to smear Azythromycin “by association.”

Remarks

This paper was published on Friday, May 22, on the eve of a long weekend. The paper immediately received wall to wall coverage in the media. On the same day The Lancet published a fawning comment Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous? These factors suggest careful coordination between the authors, the editors, and news media to catch the public and media community off-guard,causing maximum shock to reverberate over Memorial Dayweekend.

Surgisphere’s Rapid Triage, Severity Scoring, Diagnosis, Mortality Risk, advertised as artificial intelligence based tools for clinical decision support are nothing more than Javascript code, as simple as an online calculator. Additionally, this calculator is broken. Based on the company’s press releases, these tools have been covered by a range of media outlets from Yahoo! News to Breitbart. They were also covered in professional websites. Wow to those who relied on them. Unfortunately, they are easily accessible on the Surgisphere’s website.

Another Conflict of Interest?

The first author Mandeep R Mehra works in Brigham and Women’s Hospital, which conducts Gilead-initiated clinical trials of Gilead’s Remdesivir for COVID-19.

nam
BRF Oldie
Posts: 3558
Joined: 05 Jan 2017 20:48

Re: Wuhan Coronavirus Resource Thread

Postby nam » 29 May 2020 03:11

Saw some videos of Mumbai hospitals. It is really sad what is happening. Covid patients have only govt hospitals. The videos shows patients sleeping the floor, because the dead person has occupied the bed since last night!

Two other dead lie near by. Relatives mingle around patients. For every patients, you are potentially increase the infected count when you allow relatives in.

I don't understand how are non-patients allowed in to the hospital.

nam
BRF Oldie
Posts: 3558
Joined: 05 Jan 2017 20:48

Re: Wuhan Coronavirus Resource Thread

Postby nam » 29 May 2020 03:14

Niti ayog just tweet few hours back, that BMC is lying. He has not endorsed any of it's methods.

Tanaji
BRF Oldie
Posts: 3284
Joined: 21 Jun 2000 11:31

Re: Wuhan Coronavirus Resource Thread

Postby Tanaji » 29 May 2020 04:44

Mumbai municipal hospitals have been turning away patients for a week now as there is just not enough space. There are various reasons for this:

* The BMC has not started a new hospital in Mumbai limits in the last 50 years (the Sena rules BMC for last 25)
* A direct fallout from above is that a lot of primary care and hospital load is borne by small private hospitals that are single storied or just made by combining 2-3 flats together. These hospitals are now closed for various reasons such as doctors not wanting to take the risk, fear of being ostracised and the nonsensical diktat that the treatment be free or at a loss. The end result is a population of 1.2 crores has < 7 hospitals to choose from
* Multiple videos of people dying in ambulances or cars as they were turned away from civic hospitals. These deaths do not count against COVID statistics
* Apparently KEM hospital morgue is over flowing but not confirmed...

In short situation is slowly going dire


Return to “Strategic Issues & International Relations Forum”

Who is online

Users browsing this forum: kvraghav, ravikr, ryogi, s_gopal, Yagnasri and 35 guests